“We are pleased with Endo’s beat and raise quarter as the company continues to pivot itself into a more specialized company with foci on durable brands like Xiaflex, specialty injectables and a specialty generic base business. As such, the strength in the shares seen post earnings likely indicates that investors are pleased with management’s recent actions (as are we). At the same time we continue to view current debt levels, ongoing opioid litigation, and legal liabilities as significant overhangs on the name that could stunt momentum and remain HOLD rated on ENDP shares.”,” the firm’s analyst wrote.
A number of other research firms also recently issued reports on CLDX. Zacks Investment Research downgraded Celldex Therapeutics from a hold rating to a sell rating in a research note on Tuesday, May 8th. HC Wainwright set a $3.00 price target on Celldex Therapeutics and gave the stock a buy rating in a research note on Monday, April 16th. Cantor Fitzgerald downgraded Celldex Therapeutics from an overweight rating to a neutral rating and set a $3.00 price target on the stock. in a research note on Tuesday, April 17th. ValuEngine upgraded Celldex Therapeutics from a sell rating to a hold rating in a research note on Friday, June 1st. Finally, BidaskClub upgraded Celldex Therapeutics from a sell rating to a hold rating in a research note on Saturday, April 14th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and two have assigned a buy rating to the company’s stock. The company presently has a consensus rating of Hold and an average target price of $3.75.
Celldex Therapeutics (NASDAQ:CLDX) last issued its earnings results on Wednesday, August 8th. The biopharmaceutical company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.14) by $0.03. The business had revenue of $2.76 million for the quarter, compared to the consensus estimate of $2.70 million. Celldex Therapeutics had a negative return on equity of 47.40% and a negative net margin of 1,159.26%. equities research analysts anticipate that Celldex Therapeutics will post -0.51 earnings per share for the current year.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. lifted its position in Celldex Therapeutics by 1.7% during the first quarter. BlackRock Inc. now owns 10,097,481 shares of the biopharmaceutical company’s stock valued at $23,527,000 after purchasing an additional 166,780 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in Celldex Therapeutics by 74.8% during the first quarter. Dimensional Fund Advisors LP now owns 4,167,585 shares of the biopharmaceutical company’s stock valued at $9,710,000 after purchasing an additional 1,783,765 shares in the last quarter. Millennium Management LLC lifted its position in Celldex Therapeutics by 21.8% during the fourth quarter. Millennium Management LLC now owns 2,241,521 shares of the biopharmaceutical company’s stock valued at $6,366,000 after purchasing an additional 400,965 shares in the last quarter. TSP Capital Management Group LLC lifted its position in Celldex Therapeutics by 12.4% during the first quarter. TSP Capital Management Group LLC now owns 1,436,957 shares of the biopharmaceutical company’s stock valued at $3,348,000 after purchasing an additional 158,900 shares in the last quarter. Finally, Acadian Asset Management LLC lifted its position in Celldex Therapeutics by 378.4% during the second quarter. Acadian Asset Management LLC now owns 1,157,880 shares of the biopharmaceutical company’s stock valued at $583,000 after purchasing an additional 915,863 shares in the last quarter. Institutional investors own 51.86% of the company’s stock.
Celldex Therapeutics Company Profile
Celldex Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of various immunotherapy technologies and other cancer-targeting biologics. Its drug candidates include glembatumumab vedotin, an antibody-drug that is in Phase IIb study for the treatment of triple negative breast cancer and a Phase II study for the treatment of metastatic melanoma; Varlilumab, an immune modulating antibody that is in a Phase 1 study designed to enhance a patient's immune response against cancer; and CDX-3379, a human monoclonal antibody that is in Phase II study in combination with cetuximab for the treatment of head and neck squamous cell carcinoma.
Recommended Story: Trading Strategy Examples and Plans
Receive News & Ratings for Celldex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.